.

Make Better Decisions

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Drug patents in 130+ countries

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

US Department of Justice
Cerilliant
Fuji
Cantor Fitzgerald
Moodys
Teva
Daiichi Sankyo
Argus Health
QuintilesIMS
McKinsey

Generated: September 25, 2017

DrugPatentWatch Database Preview

SPRITAM Drug Profile

« Back to Dashboard

Which patents cover Spritam, and what generic Spritam alternatives are available?

Spritam is a drug marketed by Aprecia Pharms Co and is included in one NDA. There are four patents protecting this drug.

This drug has twenty-seven patent family members in eleven countries.

The generic ingredient in SPRITAM is levetiracetam. There are thirty-five drug master file entries for this compound. Ninety-six suppliers are listed for this compound. Additional details are available on the levetiracetam profile page.

Summary for Tradename: SPRITAM

Patents:4
Applicants:1
NDAs:1
Suppliers / Packagers: see list1
Bulk Api Vendors: see list95
Patent Applications: see list1,878
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:SPRITAM at DailyMed

Pharmacology for Tradename: SPRITAM

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Aprecia Pharms Co
SPRITAM
levetiracetam
TABLET, FOR SUSPENSION;ORAL207958-004Jul 31, 2015RXYesYes► Subscribe► SubscribeY ► Subscribe
Aprecia Pharms Co
SPRITAM
levetiracetam
TABLET, FOR SUSPENSION;ORAL207958-002Jul 31, 2015RXYesNo► Subscribe► SubscribeY ► Subscribe
Aprecia Pharms Co
SPRITAM
levetiracetam
TABLET, FOR SUSPENSION;ORAL207958-003Jul 31, 2015RXYesNo► Subscribe► SubscribeY ► Subscribe
Aprecia Pharms Co
SPRITAM
levetiracetam
TABLET, FOR SUSPENSION;ORAL207958-001Jul 31, 2015RXYesNo► Subscribe► SubscribeY ► Subscribe
Aprecia Pharms Co
SPRITAM
levetiracetam
TABLET, FOR SUSPENSION;ORAL207958-001Jul 31, 2015RXYesNo► Subscribe► SubscribeY ► Subscribe
Aprecia Pharms Co
SPRITAM
levetiracetam
TABLET, FOR SUSPENSION;ORAL207958-003Jul 31, 2015RXYesNo► Subscribe► SubscribeY ► Subscribe
Aprecia Pharms Co
SPRITAM
levetiracetam
TABLET, FOR SUSPENSION;ORAL207958-001Jul 31, 2015RXYesNo► Subscribe► SubscribeY ► Subscribe
Aprecia Pharms Co
SPRITAM
levetiracetam
TABLET, FOR SUSPENSION;ORAL207958-003Jul 31, 2015RXYesNo► Subscribe► SubscribeY ► Subscribe
Aprecia Pharms Co
SPRITAM
levetiracetam
TABLET, FOR SUSPENSION;ORAL207958-002Jul 31, 2015RXYesNo► Subscribe► SubscribeY ► Subscribe
Aprecia Pharms Co
SPRITAM
levetiracetam
TABLET, FOR SUSPENSION;ORAL207958-003Jul 31, 2015RXYesNo► Subscribe► Subscribe ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Tradename: SPRITAM

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,114,072Dosage form exhibiting rapid disperse properties, methods of use and process for the manufacture of same► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: SPRITAM

Country Document Number Estimated Expiration
Hong Kong1214787► Subscribe
European Patent Office2968994► Subscribe
Japan5091910► Subscribe
European Patent Office1301177► Subscribe
Mexico2015012134► Subscribe
Australia2014228990► Subscribe
Australia2017202752► Subscribe
Australia7368701► Subscribe
Japan4563516► Subscribe
Canada2906029► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: SPRITAM

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
00028Netherlands► SubscribePRODUCT NAME: LEVETIRACETAM; REGISTRATION NO/DATE: EU/1/00/146/001 - EU/1/00/146/026 20000929
00C/032Belgium► SubscribePRODUCT NAME: LEVETIRACETAM; NAT. REGISTRATION NO/DATE: EU/1/00/146/001 20000929; FIRST REGISTRATION: CH 55297 20000329
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Baxter
Covington
QuintilesIMS
Deloitte
Queensland Health
Federal Trade Commission
Cantor Fitzgerald
Express Scripts
McKesson
Healthtrust

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot